Our Guest: #2 - Spiro Rombotis, CEO at Cyclacel Pharmaceuticals
What you'll get out of this episode:
- Rombotis's background and an overview of Cyclacel
- Which part of the cell cycle they're targeting?
- What their leading candidates are, and the current clinical trial statuses of each.
- What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?
- Their PLK1 program
- Near-term milestones and what's next?
Our sponsors for this episode are Sage Growth Partners
Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners
What is BioBreakthroughs?
Welcome to BioBreakthroughs, the podcast that delves deep into the world of biotech and pharmaceuticals to bring you the latest and most exciting advancements in the field. Join us as we explore groundbreaking discoveries, cutting-edge research, and game-changing innovations that are shaping the future of healthcare. Produced by Slice of Healthcare.